Lineage Cell Therapeutics
LCTX
115 hedge funds and large institutions have $208M invested in Lineage Cell Therapeutics in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 20 closing their positions.
127% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 15
65% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 20
59% more call options, than puts
Call options by funds: $818K | Put options by funds: $514K
47% more capital invested
Capital invested by funds: $142M → $208M (+$66.6M)
13% more funds holding
Funds holding: 102 → 115 (+13)
7.8% more ownership
Funds ownership: 37.32% → 45.12% (+7.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$15.7M |
| 2 |
JP Morgan Chase
New York
|
+$5.05M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.66M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$3.45M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.35M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.4M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$785K |
| 4 |
HF
HRT Financial
New York
|
-$679K |
| 5 |
Goldman Sachs
New York
|
-$479K |
LCTX Hedge Fund Activity: Q2 2021 in Review
115 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2021, worth a combined $208M — up 47% from $142M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new LCTX positions and 20 closed out — a net gain of 13 holders — while 34 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $15.7M. The largest seller was Millennium Management, exiting entirely with an estimated $3.35M sold.
- 115 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2021, up from 102 in Q1 2021.
- Funds reported $208M of Lineage Cell Therapeutics stock for Q2 2021, up 47% quarter-over-quarter.
- 33 funds opened new Lineage Cell Therapeutics positions in Q2 2021 and 20 closed out, a net change of +13 holders.
- The largest Lineage Cell Therapeutics buyer in Q2 2021 was BlackRock, an estimated $15.7M added.
- The largest Lineage Cell Therapeutics seller in Q2 2021 was Millennium Management, an estimated $3.35M sold.
Based on aggregated 13F filings for Q2 2021.